Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Akers Biosciences, Inc. stock logo
AKER
Akers Biosciences
$0.12
-7.4%
$3.56
$1.65
$6.97
$1.95M0.3769,876 shs9.00 million shs
BG Medicine Inc. stock logo
BGMD
BG Medicine
$0.00
$0.00
$0.00
N/A2.52N/AN/A
FluoroPharma Medical Inc. stock logo
FPMI
FluoroPharma Medical
$0.00
$0.00
$0.00
N/AN/AN/AN/A
Response Genetics Inc. stock logo
RGDXQ
Response Genetics
$0.00
$0.00
$0.00
N/AN/AN/AN/A
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Akers Biosciences, Inc. stock logo
AKER
Akers Biosciences
+5.25%+9.07%-25.27%-50.95%-92.99%
BG Medicine Inc. stock logo
BGMD
BG Medicine
0.00%0.00%0.00%0.00%0.00%
FluoroPharma Medical Inc. stock logo
FPMI
FluoroPharma Medical
0.00%0.00%0.00%0.00%0.00%
Response Genetics Inc. stock logo
RGDXQ
Response Genetics
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Akers Biosciences, Inc. stock logo
AKER
Akers Biosciences
N/AN/AN/AN/AN/AN/AN/AN/A
BG Medicine Inc. stock logo
BGMD
BG Medicine
N/AN/AN/AN/AN/AN/AN/AN/A
FluoroPharma Medical Inc. stock logo
FPMI
FluoroPharma Medical
N/AN/AN/AN/AN/AN/AN/AN/A
Response Genetics Inc. stock logo
RGDXQ
Response Genetics
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Akers Biosciences, Inc. stock logo
AKER
Akers Biosciences
0.00
N/AN/AN/A
BG Medicine Inc. stock logo
BGMD
BG Medicine
0.00
N/AN/AN/A
FluoroPharma Medical Inc. stock logo
FPMI
FluoroPharma Medical
0.00
N/AN/AN/A
Response Genetics Inc. stock logo
RGDXQ
Response Genetics
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Akers Biosciences, Inc. stock logo
AKER
Akers Biosciences
$1.58M1.23N/AN/A$5.38 per share0.02
BG Medicine Inc. stock logo
BGMD
BG Medicine
N/AN/AN/AN/AN/AN/A
FluoroPharma Medical Inc. stock logo
FPMI
FluoroPharma Medical
N/AN/AN/AN/AN/AN/A
Response Genetics Inc. stock logo
RGDXQ
Response Genetics
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Akers Biosciences, Inc. stock logo
AKER
Akers Biosciences
-$3.89MN/A0.00N/AN/A-87.42%-73.31%N/A
BG Medicine Inc. stock logo
BGMD
BG Medicine
N/AN/A0.00N/AN/AN/AN/AN/AN/A
FluoroPharma Medical Inc. stock logo
FPMI
FluoroPharma Medical
N/AN/A0.00N/AN/AN/AN/AN/AN/A
Response Genetics Inc. stock logo
RGDXQ
Response Genetics
N/AN/A0.00N/AN/AN/AN/AN/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Akers Biosciences, Inc. stock logo
AKER
Akers Biosciences
N/AN/AN/AN/AN/A
BG Medicine Inc. stock logo
BGMD
BG Medicine
N/AN/AN/AN/AN/A
FluoroPharma Medical Inc. stock logo
FPMI
FluoroPharma Medical
N/AN/AN/AN/AN/A
Response Genetics Inc. stock logo
RGDXQ
Response Genetics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Akers Biosciences, Inc. stock logo
AKER
Akers Biosciences
N/A
9.22
9.22
BG Medicine Inc. stock logo
BGMD
BG Medicine
N/AN/AN/A
FluoroPharma Medical Inc. stock logo
FPMI
FluoroPharma Medical
N/AN/AN/A
Response Genetics Inc. stock logo
RGDXQ
Response Genetics
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Akers Biosciences, Inc. stock logo
AKER
Akers Biosciences
5.52%
BG Medicine Inc. stock logo
BGMD
BG Medicine
N/A
FluoroPharma Medical Inc. stock logo
FPMI
FluoroPharma Medical
N/A
Response Genetics Inc. stock logo
RGDXQ
Response Genetics
N/A

Insider Ownership

CompanyInsider Ownership
Akers Biosciences, Inc. stock logo
AKER
Akers Biosciences
0.29%
BG Medicine Inc. stock logo
BGMD
BG Medicine
6.50%
FluoroPharma Medical Inc. stock logo
FPMI
FluoroPharma Medical
36.90%
Response Genetics Inc. stock logo
RGDXQ
Response Genetics
4.85%
CompanyEmployeesShares OutstandingFree FloatOptionable
Akers Biosciences, Inc. stock logo
AKER
Akers Biosciences
416.65 millionN/ANot Optionable
BG Medicine Inc. stock logo
BGMD
BG Medicine
5N/AN/ANot Optionable
FluoroPharma Medical Inc. stock logo
FPMI
FluoroPharma Medical
4N/AN/ANot Optionable
Response Genetics Inc. stock logo
RGDXQ
Response Genetics
100N/AN/ANot Optionable

Recent News About These Companies

RGDXQ Response Genetics, Inc - Seeking Alpha
Refugee response plans
RGI to build a second West Circle commercial complex
Indigo Airlines Flights Alerted Amid Security Concerns at RGI
Genetic Variants and Escitalopram Response in MDD
Akers Biosciences stock logo

Akers Biosciences NASDAQ:AKER

Akers Biosciences, Inc. focuses on the development of a vaccine candidate against SARS-CoV-2, a coronavirus causing a pandemic. It has a collaboration agreement with Premas Biotech PVT Ltd. The company was incorporated in 1989 and is headquartered in New York, New York.

BG Medicine stock logo

BG Medicine OTCMKTS:BGMD

BG Medicine, Inc. engages in the development and commercialization of diagnostic products used to guide the patients suffering from heart failure and related disorders in the United States. The company offers BGM Galectin-3 Test, an in vitro diagnostic device that measures galectin-3 in serum or plasma by enzyme linked immunosorbent assay on a microtiter plate platform; and CardioSCORE Test, a multi-analyte biomarker-based blood test used for the assessment of near-term risk of atherothrombotic cardiovascular events, such as heart attack and ischemic stroke. It has license, development, and commercialization agreements with Abbott Laboratories, bioMérieux SA, Siemens Healthcare Diagnostics Inc., and Alere Inc. for the automated instrument versions of galectin-3 test; and a strategic collaboration with Abbott Laboratories to develop and commercialize galectin-3 assay kits, and related control kits and calibrators. The company was formerly known as Beyond Genomics, Inc. and changed its name to BG Medicine, Inc. in October 2004. BG Medicine, Inc. was founded in 2000 and is headquartered in Waltham, Massachusetts.

FluoroPharma Medical stock logo

FluoroPharma Medical OTCMKTS:FPMI

FluoroPharma Medical, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of molecular imaging pharmaceuticals with initial applications in the area of cardiology in the United States. Its product candidates include BFPET, an imaging agent that has completed a Phase I clinical trial in stress-testing for patients with presumptive or proven coronary artery disease (CAD); and CardioPET, a molecular imaging agent, which is in Phase IIa clinical trial to assess myocardial blood flow and metabolism in patients with CAD. The company has license agreements with Massachusetts General Hospital and Sinotau USA; and clinical research agreements with Pharmaceutical Product Development, LLC, as well as Cardiovascular Imaging Technologies. FluoroPharma Medical, Inc. was founded in 2003 and is headquartered in Montclair, New Jersey.

Response Genetics stock logo

Response Genetics OTCMKTS:RGDXQ

Response Genetics, Inc., a life sciences company, researches, develops, markets, and sells pharmacogenomic tests for use in the treatment of cancer in the United States, Europe, and internationally. The company offers tests for measuring predictive factors for therapy response in tumor tissue samples. It provides testing services for non-small cell lung cancer, colorectal cancer, gastric and gastroesophageal cancer, melanoma and thyroid cancer, breast cancer, and glioma through its ResponseDX: Lung, ResponseDX: Colon, ResponseDX: Gastric, ResponseDX: Melanoma, ResponseDX: Thyroid, ResponseDX: Breast, ResponseDX: Glioma, and ResponseDX: Tissue of Origin test suites. The company also develops tests for other tumor types; and provides technical component and professional component testing services. It serves community based oncologists, pathologists, physician offices, hospitals, and pharmaceutical companies through its sales force. The company was formerly known as Bio Type, Inc. and changed its name to Response Genetics, Inc. in August 2000. Response Genetics, Inc. was founded in 1999 and is headquartered in Los Angeles, California.